Perioperative management of new oral anticoagulants in patients undergoing elective surgery at a tertiary hospital.
Intern Med J. 2017 Jun 07;:
Authors: Wamala H, Scott IA, Caney X
BACKGROUND: Increasing numbers of patients receiving new oral anticoagulants (NOACs) are undergoing elective surgery. The extent to which perioperative interruption of NOAC therapy and use of bridging heparin are concordant with best evidence is uncertain.
METHODS: Retrospective study of consecutive adult patients undergoing elective surgery at a tertiary hospital between January 1(st) 2014 and June 30(th) 2015 and were receiving NOACs for at least 3 months prior to surgery. Concordance of perioperative anticoagulation management with hospital guidelines was rated by two independent researchers according to explicit thrombosis and bleeding risk tables.
RESULTS: 150 patients of mean (+/- SD) age 72.0 (+/-11.6) years were studied; 75% had atrial fibrillation as NOAC indication. Decision to interrupt anticoagulation in 142 patients was rated guideline-concordant in 59 (41.5%) based on low bleeding risk in all cases and high thrombotic risk in a third. Concordant decisions were associated with past myocardial infarction (p = 0.009), chronic kidney disease (p = 0.05), use of dabigatran (p = 0.06) and major surgery (p < 0.001). Bridging heparin was prescribed in 51 (35.9%) patients and not prescribed in 91 (64.1%), with 64 (45.1%) decisions rated guideline-discordant comprising 27 decisions to prescribe and 37 not to prescribe. Guideline concordant bridging was associated with chronic kidney disease (p = 0.02); discordant bridging with use of dabigatran (p = 0.04), high thrombotic risk (p = 0.004), past ischaemic stroke (p = 0.07). At 30 days, only one adverse event (major bleed) was noted.
CONCLUSION: Considerable discordance exists between guideline recommendations and perioperative NOAC management. Assistive tools are required that better align decision making with current best practice.
PMID: 28589690 [PubMed - as supplied by publisher]